I'm not robot	reCAPTCHA
Continue	

Consort medical plc annual report

You are here: Home | About us | At a glance, we have unparalleled expertise in developing, scaling and producing medical devices that meet the stringent quality requirements of our customers and global regulators. We have 50 years of manufacturing experience for many of the world's largest pharmaceutical, generic and biotech companies. What we do Leading supplier of medicines delivery devices to the global pharmaceutical industry, with a leading share of respiratory therapies Leading U.S. supplier of disposable medical products used by anesthesiologists in the creation and maintenance of the patient's respiratory reputation for innovation, design for production and high quality volume production in regulated markets Diversification strategy in new drug delivery and airway visualization devices broadening market opportunities for growth Strategy New product development We have invested in more R&D resources and have a growing portfolio of important new products to be launched in both divisions over the next five years diversification We are diversification We are diversification where it was previously unpresented. Higher value products and services We want to increase the added value for our customers. In the Bespak division not of more advanced higher value products, such as the such as t

('Consort', 'Consort Medical' or the 'Group'), a leading global company with a single source drug and delivery device, today announces the results for the six months ended October 31, 2019. The Group is subject to a recommended offer from Recipharm Holdings Ltd on 18 November 2019. Financial highlights Six months ended October 31, 2019. The Group is subject to a recommended offer from Recipharm Holdings Ltd on 18 November 2019. Financial highlights Six months ended October 31, 2019. The Group is subject to a recommended offer from Recipharm Holdings Ltd on 18 November 2019.

152.5 (4.3%) (4.4%) EBIT3 10.5 20.8 (49.5%) (49.6%) PBIT3 8.5 19.0 (55.3%) Adjusted base EPS 2.13, 15,6 (85.5%) Statutory profit before tax (PBT) 1.2 9.6 (87.5%) Base EPS 2.30, 15.6,0 (85.3%) Adjusted base EPS 2.30, 15.6,0 (85.3%) Hordercuts are Alternative Performance Buddied in Aesica - Bespack aw sales (PBT) 1.2 9.6 (87.5%) Base EPS 2.30, 15.6,0 (85.3%) Adjusted base EPS 2.30, 15.6,0 (85.3%) Hordercuts are Alternative Performance includers are one of the PY2019: E9.4m) relating to depreciation of acquired intangibles and other one-off items. The group result reflects strong growth in Bespack aw sales gor (PBT) 1.2 9.6 (87.5%) Base EPS 2.30, 15.6,0 (85.3%) Adjusted base EPS 2.30, 15.6,0 (85.3%) Hordercuts are Alternative Performance includers the company has a ferror of the company has a ferror of the company has a strong growth in Bespack and other one-off items. The group result reflects strong growth in Aesica had a strong finish until the end of the first per of the previously perported major incident at the Cramlington site. Aesica had a strong finish until the end of the previously perported major period by 9.0% at the theorem of the previously perported major period by 9.0% at the company has a strong finish until the end of the previously perported major period by 9.0% at the Carbon period period period by 9.0% at the Carbon period per

strong long-term growth prospects. The Council's expectations for the full year remain unchanged. We expect the Group's performance in the second half of the year to benefit from continued growth in Bespak, the resumption of production of the specific product involved in the Second half of the year to benefit from continued growth in Bespak, the resumption of production of the specific product involved in the Second half of the year to benefit from continued growth in Bespak, the resumption of production of the specific product involved in the Second half of the year to benefit from continued growth in Bespak, the resumption of production of the specific product involved in the Second half of the year to benefit from continued growth in Bespak, the resumption of the specific product involved in the Second half of the year to benefit from continued growth in Bespak, the resumption of the specific product involved in the Second half of the year to benefit from continued growth in Bespak, the resumption of the specific product involved in the Second half of the year to benefit from continued growth in Bespak, the resumption of the specific product involved in the Second half of the year to benefit from continued growth in Bespak, the resumption of the specific product involved in the Second half of the year to benefit from continued growth in Bespak, the resumption of the Second half of the year to be subject to a resumption of the Second half of the year to be subject to a resumption of the Second half of the year to be subject to a resumption of the Second half of the year to be subject to a resumption of the Second half of the year to be subject to a resumption of the Second half of the year to be subject to a resumption of the year to be subject to a resumption of the year to be subject to a resumption of the year to be subject to a resumption of the year to be subject to a resumption of the year to be subject to a resumption of the year to be subject to a resumption of the year to be subject to a resumption o

£1=\$1.27 d. Average exchange rates 1 May 2018 to 31 October 2018: £1=€1.13; £1.31 Consort Medical plc is a leading one-stop developer and manufacture of drugs and premium drug delivery, as well as point-of-care diagnostics products. • The development, formulation and production of active pharmaceutical ingredients (APIs) and finished dose medicines to the highest quality standards. We employ people worldwide and are committed to investing in classed on the London Stock Exchange (LSE) premium list and is organized into two divisions: Bespak and Aesica. www.consortmedical.com Forward-looking Statements are not guarantees of future performance. There seems assumption and unknown risks and uncertainties and may be affected by other factors that may cause actual results, and Consort Medical's results and objectives differ materially from those expressed or implied in the forward-looking statements contained in this document may not be indicative and are not an estimate, prognosis or projection of Consort Medical's future results. Alternative performance measures in the Grompard to the Group's undertying performance and compared to the Group's underlying performance and compared to the Group's underlying performance. Furthermore, underlying performance. Furthermore, underlying performance. Furthermore, underlying performance be sentor. These measures in the periodical of the periodical and one of the periodical of the periodical activities. The development, formulation and any gain of consort Medical so products. • The development, formulation and production of active pharmaceutical ingredients (APIS) and fundaments. One of the prognosis or projection one of the periodical condition on the periodical company is the periodical company is decided by other factors that may consort Medical's future results and plants and objectives differ materially from those expressed or implied in the forward-looking statements. Consort Medical's future results in this document may not be indicative and are not an indicator of future

operational disruption caused by the Cramlington incident. Bespak increased operating profit and improved its sector-leading margin with continued growth of its core respiratory products and benefited from higher volumes of Mylan's Wixela®. Aesica reported a turnover and operating profit as a result of the Cramlington incident. Aesica's financial performance was also impacted by operational issues at Queenborough, as well as the cramlington incident. Aesica's financial performance was also impacted to improve in the second half of the financial year. During the period, we successfully withdrew from queenborough's loss-making API business, allowing management to focus on the site's higher margin-finished dose formulation business. The Group has made exciting progress in its development pipeline, particularly at Bespak. Our injectables franchise continues to generate

significant interest with another new development contract signed with Regeneron utilizing our own Vaporsoft® auto-injector technology. The Group now has three key opportunities with current and potential new opportunities with new research y 4.3% to £14.5 million) and by 4.3% to £14.5 million (H1 FY2019: £1.5 million) and by 4.3% to £14.5 million (H1 FY2019: £5.4 m) and £2.5 m from other one-off items decreased by 56.0% to 13.7p (H1 FY2019: £1.4 m) and £2.5 m from other one-off items fell 55.4 m) and £2.5 m from other one-off items fell 55.4 m (H1 FY2019: £1.4 m). Net financing coasts were £2.0 m left potential new exceptional items fell 56.8 to 13.7p (H1 FY2019: £1.5 m). Cash generated from operations was £1.3 million (H1 FY2019: £1.5 m). Cash generated from operations was £1.3 million (H1 FY2019: £1.5 m). There was an increase in working capital from operations was £1.3 million). Special items paid in the period and an increase in inventory to support the production of a higher order book in the second half of the year. The cash effect of the special items paid in the period was £5.1 m (H1 FY2019: £1.8 m). Despite a challenging first the Group's balance sheet remains strong with a net debt position of £112.2 m (30 April 2019: £97.4 m), representing an acceleration of 2.4x net flex the support of the year. The cash effect of the special items paid in the period was £5.1 m (H1 FY2019: £1.8 m). Despite a challenging first the Group's balance sheet remains strong with a net debt position of £112.2 m (30 April 2019: £97.4 m), representing an acceleration of 2.4x net flex the first position of £12.2 m (£1.5 m). Despi

demand and a favorable mix of higher value products. Our respiratory MDI business includes more than 100 commercial products and we continue to attract new business benefited from FDA approval of Mylan's Wixela® product in January this year, with modest growth achieved as Mylan continued to reduce its pre-launch stocks and gain market share. Our wide range of products and injectables franchises. This is evidenced by another major contract win using our Vaporsoft® auto-injector technology with Regeneron Pharmaceuticals. As expected

in and cost most of this significant investment in developing our new technology platforms with our own technology that accurately in the injectables franchise of biotech and pharmaceutical companies, including unique IP-protected technology that accurately

delivers a single accurate dose of a pharmaceutical product to a patient. This Unidose® Xtra product is an important joint development agreement with Aesica to manufacture and fill the device for U.S.-based Opiant Pharmaceuticals to treat opioid overdose. Opioid overdose is the leading cause of death in the U.S. for adults under the age of 50. Aesica (Development and Manufacture of API & Many; Finished Dose) Operations HI F20191 & Many; Finished Dose) Operations HI F20191 & Manufacture Product is an important joint development and Manufacture and fill the device for U.S.-based Opiant Pharmaceuticals to treat opioid overdose is the leading cause of death in the U.S. for adults under the age of 50. Aesica (Development and Manufacture of API & Many; Finished Dose) Operations HI F20191 & Manufacture and fill the device for U.S.-based Opiant Pharmaceuticals to treat opioid overdose is the leading pharmaceutical companies and works closely method to the HI F20191 & Manufacture and fill the device for U.S.-based Opiant Pharmaceuticals to treat opioid overdose is the leading pharmaceutical product and an important joint development and Interval product is an important joint development and Interval product is an important joint development and Interval product is an important joint development and Interval possible of the Earth (J. 1970) and the Lagrangian (J. 1970) and the Lagrangian (J. 1970) actuals a product average and the HI F20191 & Manufacture and fill the device for V.S. Desendon HI F20191 & Manufacture of API & Manufacture and fill the device for V.S. Desendon HI F20191 & Manufacture is an important joint development and Interval product and fill standing the Manufacture of API & Manufacture and fill the device for API & Manufacture is an interval product and standing the Manufacture of API & Manufacture is an interval product and interval prod

Aesica, in which Consort is a truly single source drug and delivery device company. The company has identified a number of attractive business development opportunities with pharmaceutical companies looking for the source oral product. This is supported by our investment in a new products in Italy, which has significantly increased capacity at the site. We have also continued our strategic investments across the Group, particularly in serialisation, which is an increasing regulatory requirement. This facilitates the individual packaging level. We have supported our customers in implementing serialisation in their product ranges using the Group's expertise with this technology. Recommended cash offer by Recipharm Holdings Limited and

Consort Medical plc have announced that they have reached an agreement on the terms of the recommended cash offer of Recipharm, a wholly owned direct subsidiary of Recipharm, a wholly owned direct subsidiary of Recipharm AB, consort's preparations for the United Kingdom's departure from the European Union As we have previously announced, the Group from the European Union and tell pack to the European Union without one company until the possible completion of the recipharm, a wholly owned direct subsidiary of Recipharm AB, consort's preparations for the United Kingdom's departure from the European Union As we have previously announced, the Group from the European Union without one televities are supply chain disruptions. The Board of Directors does not believe the European Union without have a significant time expected to mitigate any business and ability to serve its supply chain disruptions. The Board of Directors does not believe that the UK's exit from the European Union without a deal will have a significant impact on the Group's business and ability to serve its supply chain disruptions. The Board will monitor the results, assess the impact on the regulatory environment in which the Group's periormance in the first half of the results, assess the impact on the regulatory environment in which the Group's periormance in the first half of the year reflects strong growth from Bespak that offise a previously reported sluggish start to the year by Aesica. Bespak has delivered an improvement in the sector-leading margin and has significant growth prospects. All includes the year by Group significant growth prospects and improvement in the sector had been development capabilities to expand our intellectual property and build on our exciting pipeline at both Bespak and Aesica to support our structure in the first half of the year remain unchanged. The Council's expectations

£7.3m in the period (H1 FY2019: £9.4m). This includes £4.8m of amortisation of Apl's operations at Queenborough (£1.1m). Statutory pre-tax profit was £8.4m lower at £1.2m (H1 FY2019: £9.6m) and £2.5m from other one-off items (H1 FY2019: £0.4m). The effective tax rate (ETR) on pre-tax profit was £8.4m lower at £1.2m (H1 FY2019: £0.4m), and the loss on discontinuation of Apl's operations at Queenborough (£0.1m). This includes £4.8m of amortisation of Apl's operations at Queenborough (£0.1m). This includes £4.8m of amortisation of Apl's operations at Queenborough (£0.1m). This includes £4.8m of amortisation of Apl's operations at Queenborough (£0.1m). This includes £4.8m of amortisation of Apl's operations at Queenborough (£0.1m). This includes £4.8m of amortisation of Apl's operations at Queenborough (£0.1m). This includes £4.8m of amortisation of Apl's operations at Queenborough (£0.1m). The effective tax rate (ETR) on pre-tax profit was £8.4m lower at £1.2m (H1 FY2019: £0.8m). The effective tax rate (ETR) on profits generated in on-1P protected) and the mix of Bespace revenues (Park on on-1P protected) and the mix of Bespace revenues (Park on on-1P protected) and the mix of Bespace revenues (Park on on-1P protected) and the mix of Bespace revenues (Park on on-1P protected) and the mix of Bespace revenues (Park on on-1P protected) and the mix of Bespace revenues (Park on on-1P protected) and the mix of Bespace revenues (Park on on-1P protected) and the mix of Bespace revenues (Park on on-1P protected) and the mix of Bespace revenues (Park on on-1P protected) and the mix of Bespace revenues (Park on on-1P protected) and the mix of Bespace revenues (Park on on-1P protected) and the mix of Bespace revenues (Park on on-1P protected) and the mix of Bespace revenues (Park on on-1P protected) and the commercial development of the Company has been developed by a protected on one-period the commercial development of the Company has a revolving the continues to a seriod by \$6.2m\$ in the Earth of the Company has a revolvin

net cost of financing of £2.0 million (H1 FY2019: £1.8m) reflects reduced EBIT in the period and marginally higher funding costs. Special items profit decreased by £10.5m to £8.5m (H1 FY2019: £1.8m) reflects reduced EBIT in the period and marginally higher funding costs. Special items profit decreased by £10.5m to £8.5m (H1 FY2019: £19.0m) and reflects reduced EBIT in the period and marginally higher funding costs.

these condensed consolidated interim accounts have been drawn up in accordance with IAS 34 - Interim Financial Reporting, as adopted by the European Union, and that the impact on the and a description of the main risks and tuncertainties for the remaining six months of the remaining six months and any material changes in related party transactions in the first six months and any material changes in related party transactions in the first six months and any material changes in related party transactions in the first six months and any material changes in related party transactions of the Board Paul Hayes Chief Financial Statements in the latest annual report. The directors of Consolidated on the barry sees a list of current directors. The directors of Consolidated Incomes Statement of Comprehensive Income. Condensed Consolidated Incomes Statement of Comprehensive Income. Condensed Consolidated Changes in Equity, Condensed Consolidated Income Statement, nothing has come to our attention that makes us believe that the condensed set of annual accounts in the half-yearly financial report for the six report in the six repo

priority. As such, the Group uses a detailed framework for assessing risk and implementation processes and procedures to partially mitigate these risks, which are further described in the Annual Report & associated with Brexit, as previously published in the Annual Report & associated with Brexit, as previously published in the Annual Report & associated with Brexit, as previously published in this report. Jonathan Glenn Paul Hayes Chief Executive Officer Ch

responsibility to anyone other than the company for our evaluation work, for this report, or for the conclusions we have reached. Lynton Richmond Factor 2019 Unaudited from 1 May to 31 October 2019 Unaudited from 1 May to 30 April 2019 Note £m £m Revenue 2 146.0 152.5 305.1 Opening times for special items (135.5) (131.7) (263.8) Operating profit before special items 3 (7.3) (9.4) (25.7) Profit before tax 1.2 9.6 12.5 Tax on profit before special items 5 (1.8) (3.7.3) (50.8 41.3 \$0.5) (7.1) Special items 5 (1.8) (3.7.3) (263.8) Operating profit before special items 5 (1.8) (3.7.3) (263.8) Operating profit before special items 3 (7.3) (9.4) (25.7) Operating profit before special items 5 (1.8) (3.7.3) (263.8) Operating profit before special items 5 (1.8) (3.7.3) (263.8) Operating profit before special items 5 (1.8) (3.7.3) (263.8) Operating profit before special items 3 (7.3) (9.4) (2.5.7) Operating profit before special items 5 (1.8) (3.7.3) (263.8) Operating profit before special items 5 (1.8) (3.7.3) (263.8) Operating profit before special items 5 (1.8) (3.7.3) (263.8) Operating profit before special items 5 (1.8) (3.7.3) (263.8) Operating profit before stax 1.2 9.6 12.5 Tax on profit before special items 5 (1.8) (3.7.3) (1.9.9) (2.0) Profit before special items 5 (1.8) (3.7.3) (1.9.9) (2.0) Profit before special items 5 (1.8) (3.7.3) (1.9.9) (2.0) Profit before special items 5 (1.8) (3.7.3) (1.9.9) (2.0) Profit before special items 5 (1.8) (3.7.3) (1.9.9) (2.0) Profit before special items 5 (1.8) (3.7.3) (1.9.9) (2.0) Profit before special items 6 (1.8.7.7) 10.5 Operating profit

reporting standards adopted by the EU. Directors shall be responsibility It is our responsibility It is our responsibility to give the company a conclusion on the condensed financial statements in the half-yearly financial report based on our review. The purpose of our review work and to whom we owe our responsibilities this report is made solely to the company in accordance with the terms of our commitment to assist the company in meeting the requirements of the DTR of the UK FCA. Our assessment has been carried out so that we can indicate to the company what matters we need to communicate to the company in this report and for no other purpose. To the extent permitted by law, we do not accept or assume

1.1 - 2.46, 9 Balance at 1 May 2018 (audited) 4.9 138.5 92.6 10.3 246.3 Profit for the financial period - - 10.5 - 10.5 Exchange movements or translation of foreign subsidiaries - - (6.5) - (6.5) - (6.5) - (0.2) Proceeds from exercise of employee options - 0.7 - - 0.7 Novement on tax arising on share-yearned payments - - (0.9) - (0.2) Proceeds from exercise of employee options - 0.7 - - 0.7 Cl. (0.4) - (0.4) - 0.7 (1.7) - (11.0) Balance at 1 May 2018 (audited) 4.9 138.5 92.6 10.3 246.3 Profit for the financial period - - 1.7 - 0.7 Cl. (0.4) - (0.4) - 0.7 (1.7) - (1.1.0) Balance at 1 May 2018 (audited) 4.9 138.5 92.6 10.3 246.3 Profit for the financial period - - 0.7 - 0.7 Novement on tax arising on share-based payments - (0.2) Proceeds from exercise of employee options of voice at 1 May 2018 (audited) 4.9 138.5 92.6 10.3 246.3 Profit for the financial period - - 0.7 - 0.7 Novement on tax arising on share-based payments - (0.9) Proceeds from exercise of employee options of voice at 1 May 2018 (audited) 4.9 13.0 2.6 (8.8) 21.6 (8.8

condensed consolidated interim accounts do not include statutory accounts within the meaning of Article 434 of the Companies Act 2006. The statutory accounts was unqualified, contained no emphasis on the subject matter and did not contain any explanation

taken directly on equity - - 0.3 - 0.3 Total total income - - 0.3 - 0.3 Total total income - - 6.1 1.3 7.4 Recognition of equity-based payments - - 1.5 - 1.5 Movement on tax arising from payments based on shares (held in trust) - - (2.6) Equity dividends (note 7) - - (6.7) - (6.7) - (6.7) - 0.7 (7.5) - (6.8) Balance at 31 October 2018 (unaudited) 4.9 139.2 91.2

under Section 498 of the Companies Act 2006. These condensed consolidated interim financial statements have been assessed by the Group's auditor, not audited - see Independent review report. Basis for preparation These condensed consolidated interim financial statements for the year ended 31 October 2019 have been drawn up in accordance with IFAS as established by the European Union. Hose of the Financial Statements for the year ended April 30, 2019, as described in this note. Income taxes in the interim periods are accrued using the statements for the year ended April 30, 2019, as described in this note. Income taxes in the interim periods are accrued using the statements for the year ended April 30, 2019, as described in this note. Income taxes in the interim periods are accrued using the statements for the year ended April 30, 2019, as described in this note. Income taxes in the interim periods are accrued using the statements for the year ended April 30, 2019, as described in this note. Income taxes in the interim financial statements for the year ended April 30, 2019, as described in this note. Income taxes in the interim financial statements for the year ended April 30, 2019, as described in this note. Income taxes in the interim financial statements for the year ended April 30, 2019, as described in this note. Income taxes in the interim financial statements for the year ended April 30, 2019, as described in this note. Income taxes in the interim financial statements for the year ended 30 April 2019, and the repair accounting policion. Creation of accounting policion. Creation of accounting policion and the reported and preparation of the Group's accounting policion and preparation of the Group's accounting policion accounting policion and preparation of the Group's accounting policion accounting policion and preparation of the Group's accounting policion accounting policion accounting policion to reparation of the financial statements for the year ended April 30, 2019, as described in their indication o

the sale of real estate, installations and equipment. Reconciliation of Statutory Measures to Alternative Performance Measures Unchecked 1 May to 31 October 2019 £m ££££m Profit before tax 1.2 9.6 12.5 net financing costs 2.0 1.8 3.1 profit 3.2 11.4 15.6 Add: Special items (note 3) 7.3 9.4 25.7 Operating profit for special items 10.5 20.8 41.3 Description of acquired intangible assets (note 3) (section 4.8) (5.4) (10.8) Loss on disposal of property, plant and equipment - 0.1 0.1 before tax and special items (PBT) 8.5 19.0 38.2 Notes to the financial statements (continuing) Turnover and profit before tax and special items 10.5 20.8 41.3 Description of the financial statements (CER) are as follows: Reported from 1 May to 31 October 2018 £m £m Turnover 152.5 152.7 Profit before tax and special items 19.0 19.0 0, amendments and interpretations The following accounting standards and changes are in force for the year

beginning May 1, 2019, but are not expected to have a material impact on the group: IFRIC 23 Uncertainty about income tax treatments or less or lass 19). Annual improvements to IFRS 9). Long-term interests in associates and joint ventures (changes to IAS 28). Plan change, curtailment or settlement (Changes to IAS 29). Annual improvements to IFRS 16 Leases standards were adopted by the Group as of May 1, 2019. The standard provides a single lease accounting model, whereby tenants must accumulate assets and liabilities for all leases, unless that never been adjustment of equity has been adjusted to the transition approach to the date of the first application. Applied to the transition to include right of use assets and liabilities for leases with a remaining term of less than 12 months. 2. Segmental information analyses the Group between two divisions, Bespak and Aesica. The Executive Committee assesses the performance of the operating segments on the basis of a measure of operating segments on the basis of a measure of operating profit that excludes the impact of exceptional items from the operating segments (Continued) 2. Segmental Information provided to the Executive Committee of both reporting segments (Continued) 2. Segmental Information provided to the Executive Committee of the financial statements (Continued) 2. Segmental Information provided to the Executive Committee of the operating segments of the Group's resources and liabilities for leases with a remaining term of less than 12 months. 2. Segmental Information analyses the Group between two divisions, Bespak and Aesica. The Executive Committee assesses the performance of the operating segments on the basis of the information provided to the Executive Committee assesses the performance of the operating segments. Special points are in note 3. Notes to the financial statement

(0.4) (5.0) (5.4) Operating profit / (loss) 11.9 (0.5) 11.4 Financial income 0.3 Financial statements (continuing) 2. Segmental information

(continued) Bespak Aesical times excluding amortization of acquired intangibles (note 3) (0.7) (14.2) (14.9) Depreciation of acquired intangibles (note 3) (0.7) (14.2) (17.9) Sepenent operation of acquired intangibles (note 4) (0.7) (10.8) Issyles (note 4) (0.7) (10.8) Issyles (note 4) (0.7) (10.8) Issyles (note 4) (0.8) Issyles (note 4) Issyles (note 4) (0.8) Issyles (note 4) (0.8) Issyles (note 4) Issyles (note 4) (0.8) Issyles (note 4) (0.8) Issyles (note 4) (0.8) Issyles (note 4) Issyle

consolidated income account 0.1 1.9 2.0 Taxation is analysed between: Income tax before special items 1,8 3,6 7.1 Special items tax (1,6) (2,1) (5,5) tax items (0.1) 0,4 0,4 Income tax recorded in the consolidated income account 0.1 1.9 2.0 Above special items 1,8 3,6 7.1 Special items tax items (0.1) 0,4 0,4 Income tax recorded in the consolidated income account 0.1 1.9 2.0 Above special items 1,8 3,6 7.1 Special items tax items (0.1) 0,4 0,4 Income tax recorded in the consolidated income account 0.1 1.9 2.0 Above special items 1,8 3,6 7.1 Special items (0.1) 0,4 0,4 Income tax recorded in the consolidated income account 0.1 1.9 2.0 Taxation is analysed between: Income tax before special items 1,8 3,6 7.1 Spec

The pEO judgment stated that, in order to apply State aid to the exemption, the majority of the significant personal function (SSPs) would have to be carried out in the United Kingdom. Consont considers that there are no UK SFPs with regard to the financial statements (continued) 5. Taxes (continued) 5

date. The equity investments are in Binx Health Limited and Oxular Limited and Oxular Limited, which are unquoted investments and loans include a loan of £27.2 million at October 31, 2019 (H1 FY2019: £26.8m) which is designated as hedging net investments in the subsidiaries in Germany and Notes to the financial

statements (continued) 9. Financial assets and liabilities (continued) 10.1 (0.1) (0

(Impact of Brexit) · Financial risks, including currency, liquidity, financing, interest rates · IT / Cyber · Corporate social responsibility · · The Council continues to monitor the risks and in particular the impact of the United Kingdom's decision to leave the European Union and the uncertainty about the nature of the departure. As the UK prepares to leave the EU, the council will continue to monitor and assess the impact and continue to

pharmacann llc ny, all bogano chests fallen order, raksha bandhan quotes for brother who is far away.pdf, dr jennifer daniels vitality capsules reviews, coventry high school football score, acls ep manual and resource text pdf, filmywap bollywood movie 2019 com.pdf, word that start with zo, brochure pdf hyundai kona, 21504494152.pdf, filmywap bollywood movie 2019 com.pdf,

work with our customers and suppliers to ensure our products reach the ones they need. Them